MAP2K7 and melanoma: Studies with KRAS inhibitors mirror earlier work, which demonstrated the ability of BRAF and MEK inhibitors to enhance the therapeutic activity of ICB in LUAD, colorectal cancer, and melanoma mouse models (61–63).